MedTrace Logo

Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

NCT07498205 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2026-04-09

No results posted yet for this study

Summary

The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.

Conditions

Interventions

DRUG

Momelotinib

200 mg daily x 96 weeks.

DRUG

Ruxolitinib

Twice daily per treating investigator discretion not to exceed protocol specified guidelines.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Alexander Coltoff, MD · SWOG Network Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-08
Primary Completion
2029-08-08
Completion
2031-08-08

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07498205 on ClinicalTrials.gov